top of page

Carisma's CEO discusses their Moderna-partnered CAR-M preclinical late breaker at #SITC23

Steven Kelly describes how Carisma is leveraging Moderna's mRNA and LNP expertise to engineer monocytes in-vivo to act as a cell therapy against cancer.



Comments


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page